David Weiss
Pulmonary Disease · Bronx, NYNPI 1619052131
Payments from drug & device makers
Across 107 payments — averaging $20.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$756
- AstraZeneca$402
- GSK$359
- AbbVie$202
- Pfizer$128
- Boehringer Ingelheim$62
- plus $239 from 12 others
What the payments were for
- Food & beverage$2,148100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 35 | $756 |
| AstraZeneca | 25 | $402 |
| GSK | 18 | $359 |
| AbbVie | 5 | $202 |
| Pfizer | 7 | $128 |
| Boehringer Ingelheim | 3 | $62 |
| Lilly USA, LLC | 2 | $29 |
| Amarin Pharma, Inc. | 2 | $29 |
| Nestle Healthcare Nutrition Inc. | 1 | $23 |
| Avanir Pharmaceuticals, Inc. | 1 | $23 |
| Mylan Specialty L.p. | 1 | $21 |
| Exact Sciences | 1 | $19 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $19 |
| Linus Health, Inc. | 1 | $18 |
| Amgen | 1 | $16 |
| Circassia Inc. | 1 | $15 |
| Phadia US Inc. | 1 | $13 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
How this compares
$2,148 in reported general payments places this provider in the 55th percentile of 1,115 pulmonary disease providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 18 | $11,329 |
| Icosapent Ethyl | 16 | $1,854 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 25 | $928 |
| Rosuvastatin Calcium | 29 | $227 |
| Losartan Potassium | 23 | $183 |
| Atorvastatin Calcium | 32 | $162 |
| Lisinopril | 18 | $148 |
| Omeprazole | 16 | $96 |
| Amlodipine Besylate | 32 | $89 |
| Metformin Hcl | 15 | $75 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $128 | $11,32918 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,115 pulmonary disease providers in New York.
Other pulmonary disease in Bronx
- Samuel DeleonBronx$1.6M
- Raji AyinlaBronx$692K
- Linda RogersNew York$7.1M
- Maria PadillaNew York$3.6M
- R WhiteRochester$3.1M
- Juan WisniveskyNew York$3M
- Bushra MinaNew York$2.5M
- Robert KanerNew York$2.3M
- Negin HajizadehGreenport$2M
- Doreen Addrizzo-HarrisNew York$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.